Qbgj398-301- A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study Of Oral Infigratinib Versus Gemcitabine With Cisplatin In Subjects With Advanced/Metastatic Or Inoperable Cholangiocarcinoma With Fgfr2 Gene Fusions/Translocations: The Proof Tri
Posted Date: May 22, 2020
- Investigator: Olugbenga Olowokure
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to determine if treatment with infigratinib improves PFS as assessed by BICR compared to treatment with gemcitabine and cisplatin in subjects with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions/ translocations
Criteria:
To Be Eligible: Must Have Unresectable Locally Advanced Or Metastatic Cholangiocarcinoma, Ecog =1, Life Expectancy >3 Months, No Prior Malignancy Within 3 Years, No Active Or History Of Infection Or Disease Impacting Safety In The Study,
Keywords:
Cholangiocarcinoma, Bile Duct Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com